BioSpace News Archive

STAAR Surgical Company, a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses for myopia, astigmatism and presbyopia, announced the appointment of Lilian Zhou to its Board of Directors, effective December 4, 2023.

EyePoint Pharmaceuticals, Inc., a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, announced that it has commenced an underwritten public offering of $175 million of shares of its common stock.

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present the next installment of its BD Innovates series, which will highlight its Pharmaceutical Systems business on Monday, December 11, 2023, at 11:30 am Eastern Time.

Xenon Pharmaceuticals Inc., a neurology-focused biopharmaceutical company, announced the closing of its previously announced underwritten public offering of 9,846,157 common shares, which includes 1,384,615 shares sold upon the full exercise of the underwriters’ option to purchase additional shares, and pre-funded warrants to purchase up to 769,230 common shares.

PDS Biotechnology Corporation announced that on December 4, 2023, PDS Biotech granted nonstatutory stock options to Lars Boesgaard, the Company’s new Chief Financial Officer, to purchase a total of 200,000 shares of the Company’s common stock as a material inducement to Mr. Boesgaard’s employment with PDS Biotech and in accordance with Nasdaq Listing Rule 5635 and PDS Biotech’s 2019 Inducement Plan.

Alto Neuroscience, Inc. today announced positive results from its Phase 2a study of ALTO-300 at the 62nd Annual Meeting of the American College of Neuropsychopharmacology (ACNP), demonstrating clinically meaningful improvements and favorable safety and tolerability in patients with major depressive disorder (MDD).

NeuroPace, Inc. (Nasdaq: NPCE), a growth-stage medical technology company focused on transforming the lives of people living with epilepsy, today announced a first of its kind strategic collaboration that will leverage RNS System’s unique biomarker monitoring and data analysis capabilities.

Aurora Spine Corporation today announced the publication of the first 6-month clinical evaluation of its ZIP™ fusion implant in the Journal of Pain Research.

TScan Therapeutics, Inc. today announced the appointment of Justin McCue, Ph.D., as its Chief Technology Officer.

EyePoint Pharmaceuticals, Inc. today announced positive topline results of its Phase 2 DAVIO 2 trial of EYP-1901, an investigational sustained delivery maintenance treatment for wet age-related macular degeneration (wet AMD) combining vorolanib, a selective tyrosine kinase inhibitor with bioerodible Durasert E™.